Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
Investor's Business Daily on MSN
IBD stock of the day Halozyme eyes two buy points; how it's 'layering' up for future growth
Halozyme is Monday's IBD Stock Of The Day. Shares are flirting with a pair of entries after the drug delivery expert issued a ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
A hidden immune cascade linking the gut and bone marrow may explain how IBD turns inflammation into colon cancer.
Although inflammatory bowel disease (IBD) starts in the gut, it doesn’t always stay there. According to a 2015 study in the journal Inflammatory Bowel Disease, up to 47% of people with IBD will ...
Researchers examined post-traumatic stress among Black and Latino individuals with inflammatory bowel diseases.
Inflammatory bowel disease (IBD) patients face significant health care access barriers, leading to medication rationing and adverse health outcomes. Key issues include appointment availability and ...
It can be overwhelming to receive a diagnosis of inflammatory bowel disease (IBD), a condition which refers to the chronic diseases that can cause inflammation in your gastrointestinal (GI) tract.
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) has been named to the Investor’s Business Daily (IBD) 2022 Best ESG Companies List. The list recognizes companies with superior Environmental, Social and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients infected with SARS-CoV-2 during the first wave ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results